Ramer Â· Alavi Nuclear Medicine Technology

More documents

Recommendations

Info

2 Radioactivity, Radiopharmacy, and Quality Assurance 11Table 2.1b. Decay factors for 99m Technetium(assuming T 1/2 = 6.0 hours)0:00 00:15 00:30 00:451.0 0.891 0.866 0.841 0.8172.0 0.794 0.771 0.749 0.7283.0 0.707 0.687 0.667 0.6484.0 0.630 0.612 0.595 0.57837) Using Table 2.1b, determine the decay factor for 99m Tcat 7 hours.a. 1.337b. 0.445c. 0.432d. 0.55138) On a Monday morning at 6:00 a.m., a technologist ispreparing a 99m Tc ECD kit that is to be used for theSPECT brain scans at 8:00 a.m., 9:00 a.m. and10:00 a.m. Each patient should receive 10 mCi. What isthe minimum activity that should be added to the kitduring preparation? Use Table 2.1a if necessary.a. 42.6 mCib. 30.0 mCic. 44.5 mCid. 52.0 mCi39) A chromatography strip is used to test a kit for radiochemicalimpurity and is counted in a well counter. PartA contains 99m Tc pertechnetate, and Part B containsbound 99m Tc in the desired form. If the results show258,000 cpm in Part B, and 55,000 cpm in Part A, can thiskit be used for injection into patients?a. yesb. no
122 Radioactivity, Radiopharmacy, and Quality Assurance40) What is the approximate labeling efficiency for the kitdescribed in question 39?a. 21%b. 79%c. 18%d. 82%41) What is the approximate radiochemical impurity of thekit described in question 39?a. 21%b. 79%c. 18%d. 82%42) A vial of 99m Tc eluate is tested for 99 Mo breakthrough,and the amount of breakthrough is 25 uCi in 775 mCiat 6:00 a.m. Following the preparation of all kits tobe used that day, 450 mCi of 99m Tc is left. That night,a technologist is asked to perform a scrotal scan at11:00 p.m. Must the generator be eluted again?a. yes, because the amount of eluate will have decayed tobelow the amount needed for a patient doseb. yes, because the molybdenum breakthrough will nowexceed the limit allowed by the NRCc. no43) A 99m Tc MDP bone scan dose was prepared at 7:00 a.m.and contained 32 mCi/2 ml. At 9:00 a.m., when thepatient arrives, the technologist realizes that the patient’sage was overlooked (13 years). The technologist wouldnow like to adjust the dose to 11 mCi. Given a 2 hourdecay factor of 0.794, what volume should be discardedso that the correct dose remains in the syringe?a. 0.65 mlb. 0.87 mlc. 1.13 mld. 1.5 ml
Page 5 and 6: Table of Contents1 Introduction . .
Page 7 and 8: 21 IntroductionIn response to all o
Page 9 and 10: 42 Radioactivity, Radiopharmacy, an
Page 11 and 12: 62 Radioactivity, Radiopharmacy, an
Page 13: 82 Radioactivity, Radiopharmacy, an
Page 21 and 22: 162 Radioactivity, Radiopharmacy, a
Page 23 and 24: 182 Radioactivity, Radiopharmacy, a
Page 25 and 26: 3 Radiation Safety1) Which of the f
Page 27 and 28: 223 Radiation Safety9) Which of the
Page 29 and 30: 243 Radiation Safety18) If the expo
Page 31 and 32: 263 Radiation Safety25) What is the
Page 33 and 34: 283 Radiation Safety33) A technolog
Page 35 and 36: 303 Radiation Safety42) What length
Page 37 and 38: 324 Instrumentation and Quality Ass
Page 53 and 54: 485 Image Presentation and Computer
Page 55 and 56: 505 Image Presentation and Computer
Page 57 and 58: 6 Skeletal System Scintigraphy1) Wh
Page 59 and 60: 546 Skeletal System Scintigraphy10)
Page 65 and 66:
606 Skeletal System Scintigraphy37)
Page 67 and 68:
7 Central Nervous System Scintigrap
Page 69 and 70:
647 Central Nervous System Scintigr
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
708 Cardiovascular System Scintigra
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
9 Respiratory System Scintigraphy1)
Page 93 and 94:
889 Respiratory System Scintigraphy
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
10 Gastrointestinal Tract Scintigra
Page 103 and 104:
9810 Gastrointestinal Tract Scintig
Page 105 and 106:
10010 Gastrointestinal Tract Scinti
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
11 Genitourinary System Scintigraph
Page 113 and 114:
10811 Genitourinary System Scintigr
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
11812 Neoplasm and Infection Scinti
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
13 Thyroid, Parathyroid,and Salivar
Page 133 and 134:
12813 Thyroid, Parathyroid, and Sal
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
14 Non-Imaging Proceduresand Radion
Page 143 and 144:
13814 Non-Imaging Procedures and Ra
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
15 Patient Care1) Which of the foll
Page 153 and 154:
14815 Patient Care10) Of the follow
Page 155 and 156:
15015 Patient Care18) According to
Page 157 and 158:
16 Mock Examination1) In which radi
Page 159 and 160:
15416 Mock Examination8) A whole bo
Page 161 and 162:
15616 Mock Examination17) The infer
Page 163 and 164:
15816 Mock ExaminationFigure 16.224
Page 165 and 166:
16016 Mock Examination29) Which of
Page 167 and 168:
16216 Mock Examination37) If a pati
Page 169 and 170:
16416 Mock Examination43) A sentine
Page 171 and 172:
16616 Mock Examination53) First pas
Page 173 and 174:
16816 Mock Examination61) What is t
Page 175 and 176:
17016 Mock Examination71) If a SPEC
Page 177 and 178:
17216 Mock Examination79) When inje
Page 179 and 180:
17416 Mock Examination87) To minimi
Page 181 and 182:
Appendix1761.a2.d3.c4.c5.b6.c7.d8.b
Page 183 and 184:
Appendix1781.c2.b3.d4.b5.c6.c7.b8.c
show all

Ramer Â· Alavi Nuclear Medicine Technology

Create successful ePaper yourself

Delete template?

Save as template?